AI Article Synopsis

  • The study aimed to evaluate the persistence of IgG antibodies in individuals who had asymptomatic infections of SARS-CoV-2, involving 1,603 participants from various medical institutions in Kanagawa, Japan.
  • After 6 months of follow-up, only 24.2% of the antibody-positive subjects maintained their IgG antibodies, indicating a much lower persistence compared to those who recovered from symptomatic COVID-19.
  • Factors such as sleeping time, drinking habits, hypertension, and medication use were found to significantly differ among groups categorized by the longevity of their antibody response.

Article Abstract

Objective To examine the continuation of antibody prevalence and background factors in antibody-positive subjects after asymptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods A study was carried out to investigate the SARS-CoV-2 antibody (IgG) prevalence. SARS-CoV-2 antibodies (IgG) were measured and analyzed with immunochromatographic tests. Patients Among 1,603 subjects, comprising patients, physicians, and nurses at 65 medical institutes in Kanagawa, Japan, 39 antibody-positive subjects received follow-up for 6 months. Results Of the 33 subjects who consented to the follow-up (23 patients and 10 medical professionals), continued positivity of IgG antibodies was confirmed in 11 of 32 cases (34.4%) after 2 months, 8 of 33 (24.2%) after 4 months, and 8 of 33 (24.2%) after 6 months. A significant difference was found in the sleeping time, drinking habits, hypertension, and use of angiotensin-receptor blockers on comparing subject background characteristics among three groups: patients with antibody production that continued for six months after the first detection of positivity, patients in whom antibody production stopped at four months, and patients in whom antibody production stopped at two months. Conclusion The continuation rate of IgG antibody prevalence was 24.2% at 6 months after the first detection of antibody positivity in cases with asymptomatic coronavirus disease 2019 (COVID-19) infections. This percentage is low compared with the antibody continuation rate in patients who have recovered from symptomatic COVID-19 infection.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851192PMC
http://dx.doi.org/10.2169/internalmedicine.8019-21DOI Listing

Publication Analysis

Top Keywords

antibody prevalence
12
months detection
12
242% months
12
patients antibody
12
antibody production
12
antibody
9
months
9
continuation antibody
8
severe acute
8
acute respiratory
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!